Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia
Authors: Barthelemy Diouf, Kristine R. Crews, Glen Lew, Deqing Pei, Cheng Cheng, Ju Bao, Jie J. Zheng, Wenjian Yang, Yiping Fan, Heather E. Wheeler, Claudia Wing, Shannon M. Delaney, Masaaki Komatsu, Steven W. Paugh, Joseph Robert McCorkle, Xiaomin Lu, Naomi J. Winick, William L. Carroll, Mignon L. Loh, Stephen P. Hunger, Meenakshi Devidas, Ching-Hon Pui, M. Eileen Dolan, Mary V. Relling, William E. Evans
Journal: JAMA (2015)

<h3>Importance</h3> With cure rates of childhood acute lymphoblastic leukemia (ALL) exceeding 85%, there is a need to mitigate treatment toxicities that can compromise quality of life, including peripheral neuropathy from vincristine treatment. <h3>Objective</h3> To identify genetic germline variants associated with the occurrence or severity of vincristine-induced peripheral neuropathy in children with ALL. <h3>Design, Setting, and Participants</h3> Genome-wide association study of patients in 1 of 2 prospective clinical trials for childhood ALL that included treatment with 36 to 39 doses of vincristine. Genome-wide single-nucleotide polymorphism (SNP) analysis and vincristine-induced peripheral neuropathy were assessed in 321 patients from whom DNA was available: 222 patients (median age, 6.0 years; range, 0.1-18.8 years) enrolled in 1994-1998 in the St Jude Children’s Research Hospital protocol Total XIIIB with toxic effects follow-up through January 2001, and 99 patients (median age, 11.4 years; range, 3.0-23.8 years) enrolled in 2007-2010 in the Children’s Oncology Group (COG) protocol AALL0433 with toxic effects follow-up through May 2011. Human leukemia cells and induced pluripotent stem cell neurons were used to assess the effects of lower<i>CEP72</i>expression on vincristine sensitivity. <h3>Exposure</h3> Treatment with vincristine at a dose of 1.5 or 2.0 mg/m<sup>2</sup>. <h3>Main Outcomes and Measures</h3> Vincristine-induced peripheral neuropathy was assessed at clinic visits using National Cancer Institute criteria and prospectively graded as mild (grade 1), moderate (grade 2), serious/disabling (grade 3), or life threatening (grade 4). <h3>Results</h3> Grade 2 to 4 vincristine-induced neuropathy during continuation therapy occurred in 28.8% of patients (64/222) in the St Jude cohort and in 22.2% (22/99) in the COG cohort. A SNP in the promoter region of the<i>CEP72</i>gene, which encodes a centrosomal protein involved in microtubule formation, had a significant association with vincristine neuropathy (meta-analysis<i>P</i> = 6.3×10<sup>−9</sup>). This SNP had a minor allele frequency of 37% (235/642), with 50 of 321 patients (16%; 95% CI, 11.6%-19.5%) homozygous for the risk allele (TT at rs924607). Among patients with the high-risk<i>CEP72</i>genotype (TT at rs924607), 28 of 50 (56%; 95% CI, 41.2%-70.0%) developed at least 1 episode of grade 2 to 4 neuropathy, a higher rate than in patients with the<i>CEP72</i>CC or CT genotypes (58/271 patients [21.4%; 95% CI, 16.9%-26.7%];<i>P</i> = 2.4×10<sup>−6</sup>). The severity of neuropathy was greater in patients homozygous for the TT genotype compared with patients with the CC or CT genotype (2.4-fold by Poisson regression [<i>P</i>&lt;.0001] and 2.7-fold based on mean grade of neuropathy: 1.23 [95% CI, 0.74-1.72] vs 0.45 [95% CI, 0.3-0.6];<i>P</i> = .004 by<i>t</i>test). Reducing<i>CEP72</i>expression in human neurons and leukemia cells increased their sensitivity to vincristine. <h3>Conclusions and Relevance</h3> In this preliminary study of children with ALL, an inherited polymorphism in the promoter region of<i>CEP72</i>was associated with increased risk and severity of vincristine-related peripheral neuropathy. If replicated in additional populations, this finding may provide a basis for safer dosing of this widely prescribed anticancer agent.